Recurrent Glioblastoma Pipeline Insight Report | 50+ Companies and 50+ Drugs

January 16 15:58 2023
Recurrent Glioblastoma Pipeline Insight Report | 50+ Companies and 50+ Drugs

DelveInsight’s, “Recurrent Glioblastoma Pipeline Insight 2023” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Recurrent Glioblastoma pipeline landscape. It covers the Recurrent Glioblastoma pipeline drug profiles, including Recurrent Glioblastoma clinical trials and nonclinical stage products. It also covers the Recurrent Glioblastoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.


Key takeaways from the Recurrent Glioblastoma Pipeline Report


  • DelveInsight’s Recurrent Glioblastoma Pipeline analysis depicts a robust space with 50+ active players working to develop 50+ Recurrent Glioblastoma pipeline treatment therapies.


  • The leading Recurrent Glioblastoma Companies are working to develop drug candidates to improve the treatment solutions include Ascletis, VBL Therapeutics, Genexine, PharmAbcine, Oncoceutics, Istari Oncology, CNS Pharmaceuticals, Oblato, Nerviano Medical Sciences, VAXIMM AG, OX2 Therapeutics, Erasca, Midatech, MediciNova, Karyopharm Therapeutics, Jiangsu Hengrui Medicine, , QED Therapeutics, Apogenix, Eli Lilly and Company, Incyte Corporation, Accendatech, Crimson BioPharm, CANbridge Life Sciences, OncoSynergy, VBI Vaccines, Calidi Biotherapeutics, Plus Therapeutics and others.


  • Promising Recurrent Glioblastoma Pipeline Therapies in various developments include ASC40, VB-111, GX-I7, Olinvacimab, ONC 201, Lerapolturev, Berubicin Hydrochloride, OKN-007, NMS-03305293, VXM01, hP1A8, ERAS-801, MTX110, MN-166, Selinexor, Camrelizumab, BGJ398, Asunercept, Abemaciclib, INCMGA00012, ACT001, CM 93, CAN008, Bemcentinib, CD200AR L, Retifanlimab, OS2966, VBI-1901, NNV2, 186RNL and many others.


  • The Recurrent Glioblastoma Companies and academics that are working to assess challenges and seek opportunities that could influence Recurrent Glioblastoma R&D. The Recurrent Glioblastoma pipeline therapies under development are focused on novel approaches to treat/improve the disease condition.


  • In the coming years, the Recurrent Glioblastoma market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.


Discover more about the recent developmental activities in the Recurrent Glioblastoma treatment landscape @ Recurrent Glioblastoma Pipeline Outlook Report


Recurrent Glioblastoma Overview


Recurrent Glioblastoma is a possibility that oncologists – and patients – must keep in mind during and after an initial course of treatment. Because it can be difficult to completely remove a tumor during surgery, there is always a possibility that the cancer might come back after a period of remission. As a result, survivors are typically scheduled for follow-up appointments and surveillance imaging every few months after the completion of their initial treatments. Glioblastoma can come back anywhere in the brain or spinal cord. However, most recurrences are found near the site of the original tumor. Without treatment, the median survival with Glioblastoma is only a few months, but even with treatment, survival is frequently only around one year. The five-year survival rate from the disease is roughly 5.0%. For people who have surgery to remove as much of the tumor as possible along with radiation and chemotherapy, the overall median survival (the time after which 50% of people have died and 50% are still alive) is only 14 months. There are treatment options for recurrent Glioblastoma, though as noted by looking at survival statistics, few of these have led to long-term survival with the disease. Some treatments do improve survival, and several can improve quality of life. That said, many of these newer treatments have only recently been evaluated in humans, and it’s too soon to know what the potential long-term benefit may be.


Recent Developmental Activities in the Recurrent Glioblastoma Treatment Landscape


  • In August 2022, Calidi Biotherapeutics announced that City of Hope received US Food and Drug Administration (FDA) authorization to proceed with a Phase I physician-sponsored clinical trial that will use Calidi’s licensed oncolytic virotherapy platform, NSC-CRAd-S-pk7 (NeuroNova), a cutting-edge therapeutic candidate comprising tumor-tropic neural stem cells delivering an oncolytic adenovirus selectively to tumor sites in patients with recurrent high-grade glioma (Calidi’s NNV-2 program).


  • In August 2022, Plus Therapeutics, presented positive data from two ongoing clinical trials of its lead investigational drug, Rhenium-186 Nanoliposome (186RNL), in the treatment of recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). 


  • In July 2021, Berubicin was granted fast track designation by the FDA for the treatment of glioblastoma multiforme (GBM) following recurrence, according to the company responsible for the agent, CNS Pharmaceuticals.


  • In March 2021, OncoSynergy, announced that the first patient was treated in the Company’s First-in-Human Phase I clinical trial evaluating OS2966 for the treatment of recurrent glioblastoma. OS2966 is a first-in-class immunotherapy, and the first ever anti-CD29 (beta 1 integrin) therapeutic to reach human trials.


  • In August 2020, ERC Belgium announced promising interim results in the Phase II clinical trial for ERC1671. The trial, ERC1671/GM CSF/Cyclophosphamide+Bevacizumab vs Placebo, is a double-blind, placebo-controlled study of 84 patients with recurrent GBM. Interim unblinding and analysis of the first 10 patients from the study demonstrated the following results in patients treated with ERC1671. Approximately 10% of the patients receiving ERC1671 experienced total recovery and survived longer than 3 years when treated following GBM recurrence and after receiving standard of care treatment. In contrast, no spontaneous remissions were observed in the control group and all patients experienced tumor progression.


Find out more about the Latest Breakthroughs of Recurrent Glioblastoma Therapies @ Recurrent Glioblastoma Treatment Landscape


Recurrent Glioblastoma Emerging Drugs Profile


ASC40: Ascletis

ASC40 is an oral, selective inhibitor of fatty acid synthase (FASN), a key enzyme which regulates de novo lipogenesis (DNL). ASC40 inhibits energy supply and disturbs membrane phospholipid composition of tumor cells by blocking de novo lipogenesis. In January 2022, Ascletis Pharma Inc. announced the dosing of the first patient in the Phase III registration clinical trial of ASC40 combined with bevacizumab for treatment of recurrent glioblastoma (rGBM). The Phase II study, completed in the U.S., in patients with rGBM has shown that the objective response rate (ORR) for ASC40 plus Bevacizumab treatment was 65% including a complete response (CR) of 20% and a partial response (PR) of 45%. 


GX-I7: Genexine

GX-I7 is a long-acting human IL-7 which is essential for homeostatic T cell proliferation and improves lymphopenia, typically induced by chemotherapy or radiation therapy. The safety has been proved via phase I clinical trial in healthy volunteers and phase Ib and Ib/2 Clinical trials are being conducted to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics and efficacy.


Olinvacimab: PharmAbcine

Olinvacimab is an anti-angiogenic antibody that neutralizes the VEGF/VEGFR2 pathway, thus inhibiting tumor growth and metastasis. It blocks the binding of all VEGFR ligands such as VEGF-A, VEGF-C and VEGF-D to VEGFR2. To gain nutrients and oxygen needed for growth, tumor cells release these VEGF ligands which promote angiogenesis (a formation of new blood vessels) that will enhance tumor blood supply. Binding of olinvacimab to VEGFR2 will result in the inhibition of VEGF-mediated tumor angiogenesis. 



VXM01 is an oral T-cell immunotherapy that is designed to activate T-cells to attack the tumor vasculature and, in several tumor types, attack cancer cells directly. VXM01 carries the vascular endothelial growth factor receptor-2 (VEGFR2), which is highly overexpressed on the tumor vasculature and on certain cancer cells as the target gene. The active, T-cell-mediated destruction of tumor vasculature cells leads to an increased infiltration of various immune cells into tumor tissue (inflammation). In preclinical studies, a murine analog VXM01 vaccine showed broad anti-tumor activity in different tumor types. This activity was linked to a VEGFR2-specific T-cell response and was accompanied by the destruction of the tumor vasculature and increased immune cell infiltration. A Phase I/II trial evaluating VXM01 in combination with avelumab, a human anti-PD-L1 antibody, for the treatment of glioblastoma is ongoing. The trial is part of a collaboration agreement with Merck KGaA, Darmstadt, Germany and Pfizer Inc. VXM01 has received orphan designation from the European Commission and from the US Food and Drug Administration (FDA) for the treatment of glioblastoma.


Recurrent Glioblastoma Therapeutics Assessment

There are approx. 50+ key companies which are developing the therapies for Recurrent Glioblastoma. The companies which have their Recurrent Glioblastoma drug candidates in the most advanced stage, i.e. phase III include, Ascletis.


Find out more about the Recurrent Glioblastoma Emerging Therapies and Companies @ Recurrent Glioblastoma Ongoing Clinical Trials Analysis


Scope of the Recurrent Glioblastoma Pipeline Report

  • Coverage- Global


  • Recurrent Glioblastoma Companies- Ascletis, VBL Therapeutics, Genexine, PharmAbcine, Oncoceutics, Istari Oncology, CNS Pharmaceuticals, Oblato, Nerviano Medical Sciences, VAXIMM AG, OX2 Therapeutics, Erasca, Midatech, MediciNova, Karyopharm Therapeutics, Jiangsu Hengrui Medicine, , QED Therapeutics, Apogenix, Eli Lilly and Company, Incyte Corporation, Accendatech, Crimson BioPharm, CANbridge Life Sciences, OncoSynergy, VBI Vaccines, Calidi Biotherapeutics, Plus Therapeutics, and others.


  • Recurrent Glioblastoma Segmentation: Phases, Molecule Type, Mechanism of Action, Route of Administration, Product Type


Table of Content

  1. Introduction
  2. Recurrent Glioblastoma Executive Summary
  3. Recurrent Glioblastoma: Overview
  4. Recurrent Glioblastoma Pipeline Therapeutics
  5. Recurrent Glioblastoma Therapeutic Assessment
  6. Recurrent Glioblastoma – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. ASC40: Ascletis
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. GX-I7: Genexine
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. VXM01: VAXIMM AG
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Recurrent Glioblastoma Key Companies
  21. Recurrent Glioblastoma Key Products
  22. Recurrent Glioblastoma- Unmet Needs
  23. Recurrent Glioblastoma- Market Drivers and Barriers
  24. Recurrent Glioblastoma- Future Perspectives and Conclusion
  25. Recurrent Glioblastoma Analyst Views
  26. Recurrent Glioblastoma Key Companies
  27. Appendix


For further information on the current Recurrent Glioblastoma Pipeline Companies and Therapies reach out to Recurrent Glioblastoma Market Drivers and Barriers


About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States